Prostatic Neoplasms clinical trials
The registry lists 6,353 studies for Prostatic Neoplasms across more than 10 countries. 1,394 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Completed
- 2,931
- Recruiting
- 1,083
- Terminated
- 617
- Active, not recruiting
- 561
- Status unknown
- 547
- Not yet recruiting
- 263
Phase
- Phase 2
- 2,011
- Phase 1
- 1,055
- Phase 3
- 591
- Phase 4
- 115
- Early Phase 1
- 108
Where
- United States
- 3,263
- Canada
- 646
- China
- 458
- France
- 453
- United Kingdom
- 438
- Italy
- 292
Who runs them
National Cancer Institute (NCI) (183) · Memorial Sloan Kettering Cancer Center (127) · M.D. Anderson Cancer Center (113) · University Health Network, Toronto (90) · AstraZeneca (78) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (71) · Jonsson Comprehensive Cancer Center (68) · Mayo Clinic (67)
Studies
Recruiting first, then most recently updated. Showing 50 of 6,353 — search for more.
- MR-Guided Cryoablation of Prostate Bed RecurrencesEnrolling by invitationNCT01727284Not applicable1 country
- Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility StudyRecruitingNCT06759701Early Phase 11 country
- Natural History Study of Early Life Exposures in Agriculture (ELEA)Enrolling by invitationNCT073285161 country
- Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate CancerRecruitingNCT06800313Phase 1/22 countries
- Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate CancerNot yet recruitingNCT07510906Not applicable1 country
- Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT06801236Phase 12 countries
- Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active SurveillanceNot yet recruitingNCT07574541Phase 21 country
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)RecruitingNCT06136650Phase 339 countries
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerNot yet recruitingNCT07667400Phase 1/21 country
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsRecruitingNCT06172478Phase 216 countries
- Micro-ultrasound-Guided Focal Laser Ablation for Intermediate-Risk Prostate Cancer: Safety & EffectivenessRecruitingNCT07339943Not applicable1 country
- Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate CancerRecruitingNCT07377006Not applicable1 country
- A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black MenRecruitingNCT07126548Not applicable1 country
- A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate CancerRecruitingNCT07082920Phase 12 countries
- A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate CancerRecruitingNCT07319871Phase 12 countries
- A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in FranceRecruitingNCT074510021 country
- Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerRecruitingNCT07181161Phase 1/210 countries
- DESTINY-PANTUMOUR04RecruitingNCT071240001 country
- Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot FlashesRecruitingNCT07729150Not applicable1 country
- IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation TherapyRecruitingNCT07686380Phase 21 country
- A Study of JNJ-98768111 in Participants With Advanced Prostate CancerRecruitingNCT07746713Phase 12 countries
- A Study of JNJ-101556143 in Participants With Metastatic Prostate CancerRecruitingNCT07832292Phase 22 countries
- A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current DrugsNot yet recruitingNCT07838753Phase 21 country
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 22 countries
- 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028RecruitingNCT05520255Phase 31 country
- A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has SpreadRecruitingNCT07543055Phase 11 country
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.RecruitingNCT07028853Phase 326 countries
- A Study in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT07719361Phase 11 country
- A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate CancerRecruitingNCT07711184Phase 12 countries
- Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center StudyNot yet recruitingNCT07830212Phase 21 country
- Precise Oncology Interventions in Nutrition and Training (OnPoint)RecruitingNCT06534918Not applicable1 country
- Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL)Not yet recruitingNCT07836933Not applicable1 country
- A Study of DXC008 in Patients With Prostate Cancer and Other Solid TumorsRecruitingNCT06926283Phase 11 country
- Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA TrialRecruitingNCT07025369Phase 21 country
- A Study of DXC014 in Patients With Advanced Solid Tumors.RecruitingNCT07177937Phase 11 country
- CV CARE: CardioVascular Care in PC PatientsRecruitingNCT06202820Not applicable1 country
- Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic AnalysisRecruitingNCT014410891 country
- Precision-Based Genomics in Prostate CancerRecruitingNCT047066631 country
- Collection of Blood From Patients With CancerRecruitingNCT000342161 country
- Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer TissueRecruitingNCT025942021 country
- Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyRecruitingNCT06780670Phase 2/313 countries
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCRecruitingNCT06855277Phase 312 countries
- Collection of Blood From Patients With Prostate CancerRecruitingNCT009232211 country
- Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyLRecruitingNCT055881281 country
- A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate CancerRecruitingNCT07570979Phase 16 countries
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Phase 17 countries
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerRecruitingNCT07213674Phase 318 countries
- Protoacoustic Imaging For 3D MappingRecruitingNCT078326171 country
- Exercise-induced Steroid Changes in Active Surveillance for Prostate CancerNot yet recruitingNCT07518888Not applicable1 country
- Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer PatientsRecruitingNCT032370261 country